Bifogade filer
Kurs & Likviditet
Prenumeration
Kalender
2025-02-21 | Bokslutskommuniké 2024 |
2024-11-21 | Kvartalsrapport 2024-Q3 |
2024-08-22 | Kvartalsrapport 2024-Q2 |
2024-05-24 | X-dag ordinarie utdelning ABLI 0.00 SEK |
2024-05-23 | Kvartalsrapport 2024-Q1 |
2024-05-23 | Årsstämma |
2024-03-26 | Extra Bolagsstämma 2024 |
2024-02-23 | Bokslutskommuniké 2023 |
2023-11-17 | Kvartalsrapport 2023-Q3 |
2023-08-18 | Kvartalsrapport 2023-Q2 |
2023-05-23 | Kvartalsrapport 2023-Q1 |
2023-05-08 | X-dag ordinarie utdelning ABLI 0.00 SEK |
2023-05-05 | Årsstämma |
2023-03-08 | Extra Bolagsstämma 2022 |
2023-02-24 | Bokslutskommuniké 2022 |
2022-11-22 | Kvartalsrapport 2022-Q3 |
2022-08-19 | Kvartalsrapport 2022-Q2 |
2022-05-31 | Kvartalsrapport 2022-Q1 |
2022-05-20 | Årsstämma |
2022-04-28 | X-dag ordinarie utdelning ABLI 0.00 SEK |
2022-02-22 | Bokslutskommuniké 2021 |
2021-11-19 | Kvartalsrapport 2021-Q3 |
2021-08-19 | Kvartalsrapport 2021-Q2 |
2021-05-21 | X-dag ordinarie utdelning ABLI 0.00 SEK |
2021-05-20 | Årsstämma |
2021-05-20 | Kvartalsrapport 2021-Q1 |
2021-04-29 | Extra Bolagsstämma 2021 |
2021-02-19 | Bokslutskommuniké 2020 |
2020-11-20 | Kvartalsrapport 2020-Q3 |
2020-08-21 | Kvartalsrapport 2020-Q2 |
2020-05-22 | X-dag ordinarie utdelning ABLI 0.00 SEK |
2020-05-20 | Årsstämma |
2020-05-20 | Kvartalsrapport 2020-Q1 |
2020-03-17 | Extra Bolagsstämma 2020 |
2020-02-19 | Bokslutskommuniké 2019 |
2019-11-20 | Kvartalsrapport 2019-Q3 |
2019-08-21 | Kvartalsrapport 2019-Q2 |
2019-05-21 | Kvartalsrapport 2019-Q1 |
2019-04-26 | X-dag ordinarie utdelning ABLI 0.00 SEK |
2019-04-25 | Årsstämma |
2019-02-28 | Bokslutskommuniké 2018 |
2019-01-17 | Extra Bolagsstämma 2018 |
2018-11-22 | Kvartalsrapport 2018-Q3 |
2018-08-21 | Kvartalsrapport 2018-Q2 |
2018-05-22 | Kvartalsrapport 2018-Q1 |
2018-04-30 | X-dag ordinarie utdelning ABLI 0.00 SEK |
2018-04-27 | Årsstämma |
2018-02-20 | Bokslutskommuniké 2017 |
2017-11-21 | Kvartalsrapport 2017-Q3 |
2017-08-17 | Kvartalsrapport 2017-Q2 |
2017-05-18 | Kvartalsrapport 2017-Q1 |
2017-04-28 | X-dag ordinarie utdelning ABLI 0.00 SEK |
2017-04-27 | Årsstämma |
2017-02-21 | Bokslutskommuniké 2016 |
2016-11-22 | Kvartalsrapport 2016-Q3 |
2016-08-18 | Kvartalsrapport 2016-Q2 |
2016-05-31 | Kvartalsrapport 2016-Q1 |
2016-04-29 | X-dag ordinarie utdelning ABLI 0.00 SEK |
2016-04-28 | Årsstämma |
2016-03-31 | Extra Bolagsstämma 2016 |
2016-02-19 | Bokslutskommuniké 2015 |
2015-11-18 | Kvartalsrapport 2015-Q3 |
2015-08-19 | Kvartalsrapport 2015-Q2 |
2015-05-20 | Kvartalsrapport 2015-Q1 |
2015-03-31 | X-dag ordinarie utdelning ABLI 0.00 SEK |
2015-03-30 | Årsstämma |
2015-02-18 | Bokslutskommuniké 2014 |
2014-11-19 | Kvartalsrapport 2014-Q3 |
2014-08-20 | Kvartalsrapport 2014-Q2 |
2014-05-12 | X-dag ordinarie utdelning ABLI 0.00 SEK |
2014-05-09 | Kvartalsrapport 2014-Q1 |
2014-05-09 | Årsstämma |
2014-02-19 | Bokslutskommuniké 2013 |
2014-01-21 | Analytiker möte 2014 |
2013-12-13 | Extra Bolagsstämma 2013 |
2013-11-20 | Kvartalsrapport 2013-Q3 |
2013-08-23 | Kvartalsrapport 2013-Q2 |
2013-05-24 | Kvartalsrapport 2013-Q1 |
2013-03-11 | X-dag ordinarie utdelning ABLI 0.00 SEK |
2013-03-08 | Årsstämma |
2013-02-05 | Bokslutskommuniké 2012 |
2012-10-15 | Kvartalsrapport 2012-Q3 |
2012-08-21 | Kvartalsrapport 2012-Q2 |
2012-06-11 | X-dag ordinarie utdelning ABLI 0.00 SEK |
2012-06-08 | Årsstämma |
2012-05-31 | Kvartalsrapport 2012-Q1 |
2012-04-02 | Extra Bolagsstämma 2012 |
2012-02-21 | Bokslutskommuniké 2011 |
2011-11-22 | Kvartalsrapport 2011-Q3 |
2011-08-23 | Kvartalsrapport 2011-Q2 |
2011-06-10 | Årsstämma |
2011-05-17 | Kvartalsrapport 2011-Q1 |
2011-02-22 | Bokslutskommuniké 2010 |
2010-11-18 | Kvartalsrapport 2010-Q3 |
2010-08-19 | Kvartalsrapport 2010-Q2 |
2010-06-11 | X-dag ordinarie utdelning ABLI 0.00 SEK |
2010-05-20 | Kvartalsrapport 2010-Q1 |
2009-11-19 | Kvartalsrapport 2009-Q3 |
Beskrivning
Land | Sverige |
---|---|
Lista | Small Cap Stockholm |
Sektor | Hälsovård |
Industri | Bioteknik |
2020 summary
KL1333 on its way to registrational Phase 2/3 study⎢Ellen Donnelly appointed new CEO of Abliva.
Important events during 2020
KL1333
- Positive feedback from the US Food and Drug Administration (“FDA”) and the UK MHRA, on the clinical development plan.
- Decision to conduct a cohesive registrational Phase 2/3 study starting in the second half of 2021.
- The first patients in the Phase 1a/b clinical study were dosed.
- The first healthy volunteers in the drug-drug interaction study (DDI study) were dosed.
NV354
- Preclinical pharmacology and safety studies entered the final phase.
Strategy and communications
- Change of company name to Abliva (formerly NeuroVive Pharmaceutical).
- Virtual Capital Markets Day in June.
- Mitochondria Day in September.
Financials
- Directed issue of SEK 20 million to Nordic life science investor Hadean Ventures in June. Dr Roger Franklin, partner at Hadean Ventures was elected as Director of Abliva’s Board.
- A preferential rights issue in May raised approximately SEK 67 million before deduction of issue costs.
Other
- Magnus Persson left the Board of Directors to focus on his role as founding partner in Eir Ventures.
Important events after the reporting period
- Ellen Donnelly was appointed new CEO February 3, 2021.
- The license agreement with Fortify Therapeutics, regarding a development of a local treatment for Leber’s Hereditary Optic Neuropathy (LHON), was terminated.
- KL1333 phase 1b - seven out of eight patients have been dosed.
- New date for the Annual General Meeting – 20 May 2021.
Financial information
October-December 2020*
- Net revenues: KSEK 112 (49)
- Other operating income: KSEK 1,602 (1,000)
- Loss before tax: KSEK 13,067 (27,112)
- Loss per share: SEK 0.04 (0.15)
- Diluted loss per share: SEK 0.04 (0.15)
January-December 2020
- Net revenues: KSEK 216 (134)
- Other operating income: KSEK 1,648 (3,500)
- Loss before tax: KSEK 59,994 (77,000)
- Loss per share: SEK 0.24 (0.45)
- Diluted loss per share: SEK 0.24 (0.45)
* APM Alternative perfomance measures, see definition on page 20.
The complete Year-End report is available for download below and through the Company’s website www.abliva.com
For more information, please contact:
Ellen Donnelly, CEO
+46 (0)46-275 62 20, ir@abliva.com
Abliva AB (publ)
Medicon Village, SE-223 81 Lund, Sweden
Tel: +46 (0)46 275 62 20 (switchboard)
info@abliva.com, www.abliva.com
For news subscription, please visit: https://abliva.com/posts/news-subscription/
Follow us on LinkedIn: https://www.linkedin.com/company/abliva
Subscribe to our YouTube channel: https://www.youtube.com/channel/UChqP7Ky5caXtp72CELhD6Mg
Abliva – Delivering mitochondrial health
Abliva develops medicines for the treatment of primary mitochondrial diseases. These congenital, rare, and often very severe diseases occur when the cell's energy provider, the mitochondria, do not function properly. The company is focused on two projects. KL1333, a powerful NAD⁺ regulator, is in clinical development and has been granted orphan drug designation in Europe and the US. NV354, an energy replacement (succinate) therapy, is in preclinical development. Abliva, based in Lund, Sweden, is listed on Nasdaq Stockholm, Sweden (ticker: ABLI).